Skip to main content

Advertisement

SpringerLink
Log in

Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

To evaluate the correlation between zidovudine (ZDV) resistance mutations of human immunodeficiency virus type 1 (HIV-1), biological parameters, and clinical evolution, 111 HIV-1-infected patients treated with ZDV were studied. Specific mutations at codons 70, 215, and 41 in the HIV-1 reverse transcriptase coding region conferring resistance to ZDV were detected using a selective polymerase chain reaction. The appearance of ZDV resistance mutations was significantly correlated with baseline clinical stage, CD4+ cell count, and viral load, but not with duration of ZDV therapy or p24 antigen level. In univariate analysis, results showed a prognostic role of mutations at codons 215 and 41 for clinical progression to the acquired immune deficiency syndrome (AIDS) or death. In multivariate analysis after controlling for viral load, CD4+ cell count, and clinical stage, the presence of the mutation at codon 215 (but not at codon 41) remained an independent predictor of subsequent clinical evolution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D, AZT Collaborative Working Group: The efficacy of azidothimidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 1987, 317: 185–191.

    Google Scholar 

  2. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy D, Dolin R, Powderly WG, Allan JD, Wong B, Merigan TC, McAuliffe VJ, Hyslop NE, Rhame FS, Balfour HH, Spector SA, Volverding, P, Petinelli C, Anderson J, AIDS Clinical Trial Group: The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. Annals of Internal Medicine 1990, 112: 727–737.

    Google Scholar 

  3. MacLeod GX, Hammer SM: Zidovudine: five years later. Annals of Internal Medicine 1992, 117: 487–501.

    Google Scholar 

  4. Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 243: 1731–1734.

    Google Scholar 

  5. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246: 1155–1158.

    Google Scholar 

  6. Boucher CAB, Tersmette M, Lange JMA, Kellam P, de Goede REY, Mulder JW, Darby G, Goudsmit J, Larder BA: Zidovudine sensitivity of human immunodeficiency viruses from high-risk symptom-free individals during therapy. Lancet 1990, 336: 585–590.

    Google Scholar 

  7. Larder BA, Kellam P, Kemp SD: Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991, 5: 137–144.

    Google Scholar 

  8. Richman DD: Clinical significance of drug resistance in human immunodeficiency virus. Clinical Infectious Diseases 1995, 21: Supplement 2: 166–169.

    Google Scholar 

  9. Montaner JSG, Singer J, Schlechter MT, Raboud JM, Tsoukas C, O'Shaughnessy M, Ruedy J, Nagai K, Salomon H, Spira B, Wainberg MA: Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the multicentre Canadian AZT trial. AIDS 1993, 7: 189–196.

    Google Scholar 

  10. D'Aquila RT, Johnson V, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD, AIDS Clinical Trials Group Protocol 116B/117 Team, Virology Committee Resistance Working Group: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Annals of Internal Medicine 1995, 122: 401–408.

    Google Scholar 

  11. Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR: RT prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after longterm zidovudine treatment. Journal of Infectious Diseases 1995, 171: 1172–1179.

    Google Scholar 

  12. Calderon EJ, Torres Y, Medrano FJ, Luque F, Larder BA, Rey C, Sanchez-Quijano A, Lissen E, Leal M: Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients. European Journal of Clinical Microbiology & Infectious Diseases 1995, 14: 512–519.

    Google Scholar 

  13. Merigan TC, Hirsch RL, Fisher AC, Meyerson LA, Goldstein G, Winters MA: The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation, and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin. AIDS 1996, 10: 159–165.

    Google Scholar 

  14. Yerly S, Denereaz N, Mermillod B, Hirschel B, Perrin L: Predictive value.of codon 215 reverse transcriptase mutation on efficacy of didanosine in HIV-infected, zidovudine-experienced patients. Antiviral Therapy 1996, 1: 167–171.

    Google Scholar 

  15. Richman DD, Grimes JM, Lagakos SW: Effect of stage of disease and drug dose on zidovudine susceptibilities of isolated human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndrome 1990, 3: 743–746.

    Google Scholar 

  16. Boucher CAB, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JMA, Goudsmit J, Larder BA: Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. Journal of Infectious Diseases 1992, 165: 105–110.

    Google Scholar 

  17. Land S, McGavin C, Lucas R, Birch C: Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy. Journal of Infectious Diseases 1992, 166: 1139–1142.

    Google Scholar 

  18. Ioannidis JPA, Cappelleri JC, Lau J, Skolnik PR, Melville B, Chalmers TC, Sacks HS: Early or deferred zidovudine therapy in HIV-infected patients without an AIDS defining illness. A meta-analysis. Annals of Internal Medicine 1995, 122: 856–866.

    Google Scholar 

  19. Jurriaans S, Weverling GJ, Goudsmit J, Boogaard J, Brok M, Van Strijp D, Lange J, Koot M, Van Gemen B: Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS. AIDS. Research and Human Retroviruses 1995, 11: 473–479.

    Google Scholar 

  20. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, Gupta P: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Annals of Internal Medicine 1995, 122: 573–579.

    Google Scholar 

  21. Tudor-William G, St Clair MH, McKinney RE, Maha M, Walter E, Santacroce S, Mintz M, O'Donnel K, Rudoll T, Vavro CL, Connor EM, Wilfert CM: HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 1992, 339: 15–19.

    Google Scholar 

  22. Shepp DH, Ashraf A, Tang ITL, Match ME, Millan C, Pergolizzi R: Reverse transcriptase genotype and antiretroviral susceptibility of human immunodeficiency virus isolates from patients with advanced disease treated with didanosine: correlation with virologic response and survival. Journal of Medical Virology 1996, 49: 303–310.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit 271, Institut National de la Santé et de la Recherche Médicale (INSERM), 151 cours Albert Thomas, 69003, Lyon, France

    K. Leriche-Guérin, M. A. Trabaud, E. Deruelle & C. Trépo

  2. Hepatogastroenterology and AIDS Unit, Hôpital Hotel Dieu, 69002, Lyon, France

    L. Cotte, F. Bissuel, P. Rougier & C. Trépo

Authors
  1. K. Leriche-Guérin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. Trabaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Cotte
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Bissuel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Deruelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Rougier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Trépo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leriche-Guérin, K., Trabaud, M.A., Cotte, L. et al. Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1. Eur. J. Clin. Microbiol. Infect. Dis. 16, 660–668 (1997). https://doi.org/10.1007/BF01708556

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01708556

Keywords

Search

Navigation